Greenhouse Funds LLLP Has $94.64 Million Stock Holdings in Phreesia, Inc. $PHR

by · The Cerbat Gem

Greenhouse Funds LLLP boosted its position in shares of Phreesia, Inc. (NYSE:PHR – Free Report) by 12.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,325,262 shares of the company’s stock after acquiring an additional 368,352 shares during the quarter. Phreesia accounts for 3.9% of Greenhouse Funds LLLP’s portfolio, making the stock its 8th biggest holding. Greenhouse Funds LLLP owned 0.06% of Phreesia worth $94,637,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of PHR. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Phreesia during the 2nd quarter valued at about $2,755,000. Panagora Asset Management Inc. boosted its holdings in shares of Phreesia by 134.9% in the second quarter. Panagora Asset Management Inc. now owns 252,354 shares of the company’s stock worth $7,182,000 after buying an additional 144,936 shares during the last quarter. Schroder Investment Management Group grew its position in Phreesia by 32.3% during the second quarter. Schroder Investment Management Group now owns 881,016 shares of the company’s stock valued at $25,074,000 after buying an additional 215,143 shares during the period. Loomis Sayles & Co. L P purchased a new stake in Phreesia during the second quarter valued at approximately $34,162,000. Finally, Norges Bank bought a new position in Phreesia in the second quarter worth approximately $1,278,000. 92.10% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on PHR shares. BMO Capital Markets initiated coverage on shares of Phreesia in a research report on Thursday, November 13th. They set an “outperform” rating and a $32.00 price objective for the company. Truist Financial boosted their price target on Phreesia from $35.00 to $36.00 and gave the company a “buy” rating in a report on Friday, September 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phreesia in a research note on Friday, October 31st. Citigroup reiterated an “outperform” rating on shares of Phreesia in a research note on Monday, September 8th. Finally, Mizuho initiated coverage on shares of Phreesia in a report on Wednesday, August 27th. They issued an “outperform” rating and a $36.00 target price for the company. Fourteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $33.86.

Check Out Our Latest Research Report on PHR

Phreesia Price Performance

Shares of NYSE:PHR opened at $20.17 on Wednesday. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -48.02 and a beta of 0.74. The firm has a fifty day moving average price of $22.28 and a 200 day moving average price of $25.38. Phreesia, Inc. has a fifty-two week low of $18.55 and a fifty-two week high of $32.76. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.12 and a current ratio of 2.12.

Phreesia (NYSE:PHR – Get Free Report) last released its quarterly earnings data on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.08. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The business had revenue of $117.26 million for the quarter, compared to the consensus estimate of $116.39 million. During the same quarter in the previous year, the company posted ($0.03) EPS. The company’s revenue was up 14.9% compared to the same quarter last year. As a group, sell-side analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Insider Buying and Selling at Phreesia

In related news, insider Evan Roberts sold 3,761 shares of the company’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total transaction of $87,556.08. Following the transaction, the insider directly owned 726,837 shares in the company, valued at approximately $16,920,765.36. This represents a 0.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Balaji Gandhi sold 4,183 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total transaction of $97,380.24. Following the completion of the sale, the chief financial officer directly owned 99,125 shares of the company’s stock, valued at approximately $2,307,630. The trade was a 4.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 26,174 shares of company stock valued at $603,835. Insiders own 5.50% of the company’s stock.

Phreesia Profile

(Free Report)

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

Featured Stories

Want to see what other hedge funds are holding PHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phreesia, Inc. (NYSE:PHR – Free Report).